Home / Market News / $AMRZ
benzinga Corporate Catalyst Impact 55/100 ● neutral

Barclays Maintains Equal-Weight on Amrize, Lowers Price Target to $40

Oct 19, 2026, 6:50 PM UTC · Primary ticker $AMRZ

Barclays analyst Adam Seiden has lowered the price target for Amrize (AMRZ) from $55 to $40, while maintaining an 'Equal-Weight' rating. This indicates a revised, less optimistic outlook on the stock's future valuation, which could pressure the stock in the short term.

Barclays analyst Adam Seiden has reduced the price target for Amrize (AMRZ) from $55 to $40, signaling a more cautious valuation outlook. While the 'Equal-Weight' rating suggests the analyst believes the stock will perform in line with the broader market, the significant price target reduction indicates a perceived decrease in the company's intrinsic value or future growth prospects. This news primarily affects current and potential investors in Amrize, as it could lead to downward pressure on the stock price in the short term. For traders, this presents a potential opportunity for short positions or to re-evaluate existing long positions, as the analyst's revised target might influence market sentiment and institutional buying/selling decisions.

$AMRZ negative Price target lowered
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.